TY - JOUR
T1 - Multidisciplinary management of advanced kidney cancer
AU - LaGrange, Chad A.
AU - Dror Michaelson, M.
AU - Tetzlaff, Colleen H.
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2020/7
Y1 - 2020/7
N2 - A number of therapeutic options are available for the treatment of advanced kidney cancer, including targeted therapy, immunotherapy, and nephrectomy. Choice of therapy for advanced kidney cancer is guided by risk stratification. Immunotherapy combinations are generally superior to vascular endothelial growth factor-based monotherapy, and overall survival rates continue to increase substantially. With new systemic therapy options, additional improvements have been noted in durable responses to treatment and in quality of life. Nephrectomy remains an important consideration in selected patients, particularly those with minimal burden of metastatic disease. Managing the adverse events of treatment of advanced kidney cancer requires close attention and multidisciplinary collaboration.
AB - A number of therapeutic options are available for the treatment of advanced kidney cancer, including targeted therapy, immunotherapy, and nephrectomy. Choice of therapy for advanced kidney cancer is guided by risk stratification. Immunotherapy combinations are generally superior to vascular endothelial growth factor-based monotherapy, and overall survival rates continue to increase substantially. With new systemic therapy options, additional improvements have been noted in durable responses to treatment and in quality of life. Nephrectomy remains an important consideration in selected patients, particularly those with minimal burden of metastatic disease. Managing the adverse events of treatment of advanced kidney cancer requires close attention and multidisciplinary collaboration.
UR - http://www.scopus.com/inward/record.url?scp=85090856191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090856191&partnerID=8YFLogxK
U2 - 10.6004/JNCCN.2020.5017
DO - 10.6004/JNCCN.2020.5017
M3 - Article
AN - SCOPUS:85090856191
SN - 1540-1405
VL - 18
SP - 977
EP - 981
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 75
ER -